Adults 18 to 99, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Rate of CompletionPrimary· 7 days
Rate of subjects who complete the 7-day course of Maraviroc (or shorter if discharged from hospital prior to 7 days) without discontinuation for serious adverse event or death.
Group
Value
95% CI
Maraviroc Treatment
7
Clinical Improvement at Day 7Primary· 7 days
Percent of patients at Day 7 from enrollment achieving reduction of two points on a seven-category ordinal scale (defined below).
Ordinal scale: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities OR hospitalized pending disposition, not requiring COVID-related care; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilat
Group
Value
95% CI
Maraviroc Group
3
MortalitySecondary· 28 days
7-, 14- and 28-day all-cause-mortality
7-Day Mortality
Group
Value
95% CI
Maraviroc Treatment
0
14-Day Mortality
Group
Value
95% CI
Maraviroc Treatment
0
28-Day Mortality
Group
Value
95% CI
Maraviroc Treatment
0
Median Time to >= 2 Point Improvement in Clinical Score.Secondary· 28 Days
If no clinical improvement of \>=2 points met by day 28, patient outcome censored
Group
Value
95% CI
Maraviroc Treatment
8
5 – 28
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected over 35 days from day of enrollement..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell trafficking of inflammatory cells, both increasing viral control capacity and dampening damage to lung tissue, respectively. This study seeks to establish whether one week of treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06853223 — This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
· Phase 2
· recruiting
NCT06805656 — Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals
· Phase 2
· not yet recruiting
NCT05470491 — Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
· Phase 1, PHASE2
· recruiting
NCT03274804 — Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
· Phase 1
· completed
NCT04965662 — The Role of Home Packs of HIV PEPSE in High Risk Individuals
· Phase 4
· completed
Other recruiting trials for COVID
Currently open trials in the same condition.
NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rhode Island Hospital
Last refreshed: 29 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04435522.